NEWS RELEASE

Teijin Launches Teijin Meguro Instituteto Strengthen Functional Food Ingredients BusinessTokyo, Japan, October 3, 2022 --- Teijin Limited announced today its launch of the Teijin
Meguro Institute Co., Ltd. to strengthen the company’s development and manufacture ofprobiotics for use in functional foods. The new firm will provide functional food ingredientsthat meet the demands of health-conscious consumers by leveraging its predecessor’sexpertise in probiotics, which are microorganisms that benefit human health by improving
the balance of intestinal lactic acid bacteria, etc. and the prebiotics that feed them.
Teijin Meguro Institute, the new wholly owned subsidiary of Teijin Limited, has inherited
the personnel and equipment of its predecessor, Meguro Institute. The former company
was established in 1925 as the Osaka Experimental Therapy Institute by the late Dr.
Yosaburo Meguro, an abacteriologist and immunologist who studied at the Kitasato
Institute and the Pasteur Institute. In 1937, the company name was changed to Meguro
Institute, and it manufactured, sold and handled outsourced business involving lactic acidbacteria and Bacillus subtilis natto for use in pharmaceuticals, functional foods and feed
additives backed by its excellent expertise in culturing bacteria, manufacturing method
and stable supply. In August, Teijin signed a share-transfer agreement with Maruishi
Pharmaceutical Co., Ltd., the parent company of Meguro Research Institute, andsubsequently received 100% of the firm’s shares. The new company, while continuing toconduct research, manufacturing and sales of lactic acid bacteria and Bacillus subtilis
natto, also will work to commercialize promising microorganisms currently being
developed by Teijin.
The newly appointed president of Teijin Meguro Institute is Takanori Miyoshi, who has
engaged in basic research into polymer materials since joining Teijin in 1992 as well as
research and development of functional-food ingredients since 2013.
Overview of Teijin Meguro Institute
Official Name
Teijin Meguro Institute Co., Ltd.
Head Office
2-6-4 Fushimimachi, Chuo-ku, Osaka, Japan
President
Takanori Miyoshi
CapitalJPY 35.2 million
Employees
24 (October 2022)
Manufacture, sale and import of ingredients for pharmaceuticals,
Businessfunctional foods, feed additives, etc.
Sales
JPY 730 million in FY2021 (Meguro Institute Co., Ltd.)
Teijin expects to enhance the probiotics division of its functional food ingredientsbusiness by merging its own research, development and marketing capabilities with thetechnologies, knowhow and sales network of Teijin Meguro Institute. In conjunction withthe launch, Teijin has changed the name of its “Functional Food Ingredient Business
Development Project” to the “Biolier Division.” “Biolier” originally is Teijin’s functional foodingredient business tradename in Japan emphasizing its status as one of a few
companies involved with synbiotics, which synergistically combine the functions ofprebiotics and probiotics. Going forward, Teijin expects to accelerate the growth of its
functional food ingredients line, part of the company’s overall healthcare business, undera mission of enhancing human quality of life to help people worldwide enjoy fulfilling lives
from birth to their final days.
Teijin’s prebiotics lineup in Japan includes BARLEYmax™ super barley sold since 2016
and water-soluble dietary fiber sold since 2018. In 2020, Teijin expanded into probiotics
and signed a sales agency agreement with Chr. Hansen Holding A/S, a leading supplierof probiotics, to sell materials and products such as lactic acid bacteria and bifidobacteria.
In addition, Teijin created the “Biolier” tradename in Japan in 2020 for its entire functional
food ingredient lineup to help position the company as a “bio sommelier” backed byscientific evidence and now uses “Biolier” in its new business division name to show thecompany’s intention to expand its related business globally.
In recent years, the market for lactic-acid bacteria, bifidobacteria and other probiotics
has expanded rapidly amid the general public’s growing interest in immunity due to theCOVID-19 pandemic. The global market, valued at roughly USD 3.5 billion in 2021, isexpected to surpass USD 6 billion by 2028 according to a report issued by InsightPartners on June 17.
About the Teijin GroupTeijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company thatsupports the society of the future. The group comprises some 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD
9.4 billion) in the fiscal year that ended on March 31, 2022.
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp